Code ATC: N06BX03
Pyracetam is a nootropic agent, it has a positive effect on metabolism of brain, increases concentration of ATP in brain, enhances biosynthesis of ribonucleic acid and phospholipids, stimulates glycolytic processes, enhances glucose utilization. The drug enhances integrative activity of brain, improves memory, it has a protective effect in various forms of cerebral hypoxia, it facilitates learning process.
The drug improves communication between hemispheres of brain and synoptic conductivity in neocortical structures, restores and stabilizes cerebral functions, especially of consciousness, memory and speech, enhances mental performance and improves cerebral blood flow.
Psychoorganic disorders of vascular and toxic genesis (comatose conditions, acute phase of traumatic brain injury, recovery periods of ischemic stroke): psychoorganic syndromes with a predominance of asthenia, reduced attention and cognitive abilities (cerebral arteriosclerosis, intoxication, alcoholism), alcohol withdrawal and relief of alcoholic delirium, acute poisoning with morphine and barbiturates, psychoses and asthenic depressive conditions, apathetic-abulic manifestations of schizophrenia, depressions resistant to antidepressants. Memory impairment, dizziness, Alzheimer's disease, arteriosclerotic encephalopathy, post stroke mental and physical defects. Prevention and treatment of neonatal asphyxia, birth trauma and it’s aftermath, the period of convalescence after meningitis, encephalitis, traumatic brain injury, mental retardation, learning difficulties. Disorders of memory and intellectual impairment. Correction of side effects and complications of therapy by psychotropic drugs, and epilepsy. Cortical myoclonia. Sickle-cell anemia. Viral neuroinfections.
20 % solution for injections, in ampoules of 5 ml.